SBIR Phase II Grant Awarded for Next Generation NPWT and Delivery Platform

    April 4, 2015 Newton, Massachusetts Applied Tissue Technologies has been awarded a Phase II SBIR grant to further investigate it's next generation NPWT (negative pressure wound therapy) under contract # W81XWH-14-C-0015 and sponsored by the DHP/ Army.  Click to follow link to SBIR reference page. The two year…

Continue Reading SBIR Phase II Grant Awarded for Next Generation NPWT and Delivery Platform

Japan Issues New Patent for Next Generation Negative Pressure Wound Therapy Device

October 10, 2014 Newton, MA Applied Tissue Technologies was issued yet another patent for their new next generation negative pressure device. The device eliminates the use of an intermediary layer such as foam or gauze with the use of an innovative and proprietary design utilizing microstructures. The elimination of the…

Continue Reading Japan Issues New Patent for Next Generation Negative Pressure Wound Therapy Device

Another New Patent for Applied Tissue Technologies NPWT technology. Innovative technology and simplified design eliminates the foam or gauze wound filler.

April 17, 2014 Newton, Massachusetts Applied Tissue Technologies LLC announces news in advanced wound care with: An additional patent for simplifying the use of negative pressure wound therapy with a breakthrough design. The new patent is granted in China. The technology simplifies the administration of negative pressure wound therapy “NPWT”…

Continue Reading Another New Patent for Applied Tissue Technologies NPWT technology. Innovative technology and simplified design eliminates the foam or gauze wound filler.

Applied Tissue Technologies Announces additional Patent for next generation negative pressure wound therapy device

April 10, 2014 Newton, Massachusetts Applied Tissue Technologies LLC announces news in advanced wound care with: An additional patent for simplifying the use of negative pressure wound therapy with a breakthrough design. The new patent is allowed in Australia. The technology simplifies the administration of negative pressure wound therapy “NPWT”…

Continue Reading Applied Tissue Technologies Announces additional Patent for next generation negative pressure wound therapy device

Applied Tissue Technologies Breakthrough NPWT design wins SBIR grant

      February 4, 2014 Newton, Massachusetts Following on the heels of the issuance of USPTO patent number 8,632,523, describing a revolutionary method and device to administer Negative Pressure Wound Therapy (NPWT), Applied Tissue Technologies has been awarded a Phase I SBIR grant to investigate negative pressure wound therapy…

Continue Reading Applied Tissue Technologies Breakthrough NPWT design wins SBIR grant

Applied Tissue Technologies announces the issuance of a new patent simplifying the use of negative pressure wound therapy with a breakthrough design

      January 30, 2014 Newton, Massachusetts Applied Tissue Technologies LLC announces news in advanced wound care with: The issuance of a new patent simplifying the use of negative pressure wound therapy with a breakthrough design. The USPTO patent entitled "Wound Treatment Device Employing Negative Pressure," was issued on…

Continue Reading Applied Tissue Technologies announces the issuance of a new patent simplifying the use of negative pressure wound therapy with a breakthrough design

ISO 13485:2003 Certified

Applied Tissue Technologies LLC has obtained ISO 13485 certification using BSI as its notified body.  We have also secured CMDCAS certification in Canada for the Xpansion Skin Grafting Instruments and continue to work toward CE certification for distribution in Europe.

Continue Reading ISO 13485:2003 Certified

Clinical Trials to begin at Southern Illinois University and McGill University

Applied Tissue Technologies has enrolled the Xpansion Skin Grafting Instrument kit in two clinical trials.  The trials will start in the 2nd quarter of 2013, and provide data to support the efficacy of the device and procedure (to transplant minced split thickness skin autografts (STSG)s.  Additionally the use of negative…

Continue Reading Clinical Trials to begin at Southern Illinois University and McGill University